Abstract
We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.
| Dokumententyp: | Zeitschriftenartikel | 
|---|---|
| Fakultät: | Medizin | 
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit | 
| URN: | urn:nbn:de:bvb:19-epub-6609-7 | 
| Dokumenten ID: | 6609 | 
| Datum der Veröffentlichung auf Open Access LMU: | 21. Okt. 2008 09:33 | 
| Letzte Änderungen: | 29. Apr. 2016 09:00 | 
 
		 
	 
    



